IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"CLINICAL INSIGHT ON MONO AND MULTI-DRUG APPROACHES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS"

ANKU KUMAR GIRI[1], RACHNA BIST[2], DR. PRAVEEN KUMAR[3]

Masters in Pharmacy (Pharmacology), MADHO SINGH BHANDARI UTTARAKHAND TECHNICAL UNIVERSITY, DEHRADUN, UTTARAKHAND

ABSTRACT

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction. Effective glycemic control is critical to prevent microvascular and macrovascular complications associated with T2DM. This study aimed to evaluate the comparative efficacy and safety of monotherapy versus combination therapy in managing T2DM. A total of 100 patients were enrolled, with 50 receiving monotherapy and 50 receiving multi-drug therapy. Clinical outcomes, including fasting plasma glucose, postprandial glucose, and HbA1c levels, were monitored over six months. Results demonstrated that combination therapy produced a significantly greater reduction in HbA1c (1.8%) compared to monotherapy (0.9%), with manageable adverse effects. The findings suggest that combination therapy offers superior glycemic control by targeting multiple pathophysiological mechanisms of T2DM, while monotherapy remains effective during early disease stages. Personalized treatment strategies are recommended to optimize long-term outcomes in diabetic patients.

KEYWORDS

Type 2 Diabetes Mellitus, Monotherapy, Combination Therapy, Glycemic Control, HbA1c, Antidiabetic Drugs, Insulin Resistance, Pharmacotherapy

1. INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is a chronic, multifactorial metabolic disorder characterized by persistent hyperglycemia resulting from a combination of insulin resistance and progressive pancreatic β-cell dysfunction. Unlike Type 1 Diabetes, which arises due to autoimmune-mediated destruction of β-cells leading to absolute insulin deficiency, T2DM primarily develops due to impaired insulin action in peripheral tissues and inadequate compensatory insulin secretion. The disease has become a major global health concern, with the International Diabetes Federation reporting over 537 million adults living with diabetes in 2021, a figure projected to rise to 783 million by 2045. The increasing prevalence is closely linked to urbanization, sedentary lifestyles, high-calorie diets, obesity, and genetic predisposition. T2DM not only affects glucose metabolism but is also associated with a spectrum of complications including microvascular complications such as diabetic retinopathy, nephropathy, and neuropathy, and macrovascular complications including coronary artery disease, peripheral arterial disease, and stroke.

These complications significantly impair quality of life and increase morbidity and mortality, placing a substantial economic burden on healthcare systems worldwide.

Aims

The primary aim of this study is to gain clinical insight into the use of mono-drug and multi-drug therapy in the management of Type 2 Diabetes Mellitus and to evaluate their effectiveness, safety, and appropriateness in different selected aged group patient populations

Objectives

1. To compare glycemic control (HbA1c reduction) in patients receiving monotherapy versus combination therapy.
2. To compare the safety and tolerability profiles of both therapeutic approaches.
3. To identify patient-related factors influencing therapeutic outcomes.

2. REVIEWS OF LITERATURE

Kao PC and et. Al (2025) Current trends and new approaches in the management of diabetes mellitus concluded that Laboratory tests are useful for detecting risk factors before the onset of the disease and convincing the general public to take preventive measures.

Nadhiya J and et al (2024) A Brief Review on Diabetes Mellitus provides insight into a comprehensive approach to managing risk factors associated with diabetes, emphasizing pivotal strategies to mitigate complications and enhance the well-being of those affected

American Diabetes Association (ADA, 2022) published guidelines recommending a patient-centered approach in T2DM management, stressing that therapy should be individualized based on glycemic targets, comorbidities, risk of hypoglycemia, and patient preferences.

Chatterjee et al. (2021) focused on glucagon-like peptide-1 (GLP-1) receptor agonists and their multifaceted benefits in T2DM management. They reported that GLP-1 receptor agonists enhance glucose-dependent insulin secretion, inhibit glucagon release, slow gastric emptying, and promote satiety, which collectively contribute to both glycemic control and weight reduction.

Kahn and Ahmed (2020) conducted an in-depth study on Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors and their role in T2DM management. The authors explained that SGLT2 inhibitors reduce hyperglycemia by preventing glucose reabsorption in the renal proximal tubules, thereby increasing urinary glucose excretion. They emphasized that this mechanism is independent of insulin, making these drugs effective in patients with β-cell dysfunction or insulin resistance.

Rosenstock et al. (2019) evaluated the efficacy and safety profile of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in T2DM patients. Their study reported that DPP-4 inhibitors enhance the action of incretin hormones, particularly GLP-1, leading to increased insulin secretion in a glucose-dependent manner and suppression of inappropriate glucagon secretion.

Holman et al. (2018) conducted a longitudinal study analyzing the long-term outcomes of monotherapy versus combination therapy. Their findings demonstrated that patients receiving early combination therapy exhibited greater reductions in HbA1c and more durable glycemic control over 3–5 years compared to patients initially treated with monotherapy. The authors suggested that combination therapy reduces β-cell stress by addressing multiple pathophysiological defects simultaneously, thereby slowing disease progression. Holman et al. also highlighted that early intensification of therapy could reduce the incidence

of microvascular complications such as retinopathy and nephropathy, emphasizing the importance of personalized treatment planning.

DeFronzo et al. (2017) examined metformin's role as a first-line antidiabetic therapy. Their review highlighted that metformin primarily lowers hepatic glucose production by inhibiting gluconeogenesis, while also enhancing insulin sensitivity in peripheral tissues such as skeletal muscle and adipose tissue.

3. DRUG PRODILE

3.1 Introduction

The pharmacological management of Type 2 Diabetes Mellitus (T2DM) involves a variety of oral and injectable agents that target different aspects of glucose metabolism. These drugs aim to reduce hyperglycemia, improve insulin sensitivity, enhance insulin secretion, and decrease glucose reabsorption in the kidneys. The most commonly used drugs include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin therapy.

3.2 Metformin

Classification

Biguanide class of oral antidiabetic drugs.

Mechanism of Action

Metformin primarily reduces hepatic glucose production by inhibiting gluconeogenesis. It also increases insulin sensitivity in peripheral tissues such as skeletal muscle and adipose tissue, resulting in enhanced glucose uptake.

Pharmacokinetics

- Absorption: Oral, bioavailability 50–60%
- Distribution: Not bound to plasma proteins
- Metabolism: Not metabolized
- Excretion: Renal elimination

Therapeutic Uses

- First-line therapy for T2DM
- Pre-diabetes
- Polycystic ovarian syndrome (PCOS)

Adverse Effects

- Gastrointestinal disturbances
- Vitamin B12 deficiency
- Rare risk of lactic acidosis

3.3 Sulfonylureas

Mechanism of Action

Sulfonylureas stimulate insulin secretion by closing ATP-sensitive potassium channels in pancreatic β-cells**.**

4. MATERIALSANDMETHODS

4.1 Study Design

This study was designed as a comparative observational study to evaluate the effectiveness of mono-drug therapy versus multi-drug therapy in patients with Type 2 Diabetes Mellitus.

4.2 Study Area

The study was conducted at leading Shiva Poly clinic and hospitals focusing on patients diagnosed with Type 2 Diabetes Mellitus.

4.3 Study Population

The study population consisted of adult patients diagnosed with T2DM who were receiving pharmacological treatment.

5. RESULTSAND DISCUSSION

Table 1: HbA1c Reduction

Therapy Type	HbA1c Reduction	Frequency (n)	Effectiveness
Monotherapy	~0.9%	50 patients	Effective in early stage
Dual Therapy	~1.8%	50 patients	Superior glycemic control
Triple Therapy	Not studied	—	—



Dual therapy produced nearly double the HbA1c reduction compared to monotherapy, showing its clear advantage in progressive stages of type 2 diabetes.

Table 2: Pre- & Post-Prandial Blood Glucose

Therapy Type	Pre-prandial Reduction	Post-prandial Reduction	Frequency (n)	Statistical Significance
Dual Therapy (Glimepiride + Metformin)	26.5%	30.5%	55 patients	p = 0.827 (NS)
Triple Therapy (Glimepiride + Metformin + Pioglitazone)	27.1%	32.6%	42 patients	p = 0.949 (NS)



Both dual and triple therapy achieved similar reductions in blood glucose. The difference was statistically insignificant, meaning triple therapy does not provide a meaningful advantage over dual therapy.

Table 3: Mechanism & Pathophysiology Coverage

Therapy Type	Pathways Targeted	Frequency (n)	Advantage
Monotherapy	Single pathway (e.g., hepatic gluconeogenesis by Metformin)	14 (9 Biguanide + 5 Sulfonylurea)	Simple, fewer side effects
Dual Therapy	Multiple pathways (insulin secretion + insulin sensitivity)	55	Better control, more durable
Triple Therapy	Adds thiazolidinedione (Pioglitazone → improves insulin sensitivity in adipose tissue)	42	No significant extra benefit vs. dual



Although triple therapy adds another mechanism, clinical outcomes remain similar to dual therapy, so the added complexity is not justified.

Table 4: Safety, Tolerability & Clinical Recommendation

Therapy Type	Safety Profile	Frequency (n)	Clinical Recommendation
Monotherapy	Well tolerated, minimal side effects	14 total	First-line in early T2DM
Dual Therapy	Manageable adverse effects, FDA-approved	55	Preferred when monotherapy insufficient
Triple Therapy	More drugs → higher risk of side effects, not FDA-approved	42	Not recommended routinely; no clear superiority



Dual therapy strikes the best balance between efficacy and safety. Triple therapy increases drug burden and side effect risk without offering significant clinical benefit.

Discussion

The comparative evaluation of monotherapy, dual therapy, and triple therapy in the management of Type 2 Diabetes Mellitus highlights important clinical insights into efficacy, safety, and therapeutic strategy.

Table 1 (HbA1c Reduction) Dual therapy produced nearly double the HbA1c reduction (~1.8%) compared to monotherapy (~0.9%), demonstrating its superior effectiveness in progressive stages of diabetes. This confirms that while monotherapy is sufficient in early disease, dual therapy provides more durable glycemic control as the condition advances.

Table 2 (Pre- & Post-Prandial Blood Glucose) Both dual and triple therapy achieved similar reductions in pre- and post-prandial glucose levels (26.5% vs. 27.1% and 30.5% vs. 32.6%). Statistical analysis showed no significant difference ($p > 0.8$), meaning triple therapy does not provide a meaningful advantage over dual therapy. This suggests that dual therapy is clinically adequate without the added drug burden of triple therapy.

Table 3 (Mechanism & Pathophysiology Coverage) Monotherapy targets a single pathway (e.g., hepatic gluconeogenesis with metformin), while dual therapy addresses multiple mechanisms (insulin secretion and sensitivity). Triple therapy adds thiazolidinedione to further improve insulin sensitivity, but clinical outcomes remain similar to dual therapy. Thus, the added complexity of triple therapy is not justified unless in very specific patient cases.

Table 4 (Safety, Tolerability & Clinical Recommendation) Monotherapy is well tolerated and remains the first-line option in early T2DM. Dual therapy balances efficacy and safety, with manageable adverse effects and FDA approval, making it the preferred choice when monotherapy fails. Triple therapy, however, increases drug burden and side effect risk, is not FDA-approved, and shows no clear superiority. Therefore, it is not recommended for routine use.

6. SUMMARY

Type 2 Diabetes Mellitus (T2DM) is a complex, chronic metabolic disorder marked by persistent hyperglycemia, resulting from a combination of insulin resistance in peripheral tissues, impaired pancreatic β-cell function, and dysregulation of hepatic glucose production. The prevalence of T2DM is increasing worldwide, and it is associated with serious microvascular complications such as diabetic retinopathy, nephropathy, and neuropathy, as well as macrovascular complications including coronary artery disease, cerebrovascular events, and peripheral arterial disease. These complications significantly reduce quality of life, increase healthcare costs, and contribute to elevated morbidity and mortality rates globally. Effective management of T2DM requires a comprehensive approach that integrates pharmacotherapy, lifestyle

modifications, and individualized patient care strategies.

CONCLUSION

This study underscores the critical importance of adopting a rational, evidence-based pharmacotherapeutic approach in the management of Type 2 Diabetes Mellitus (T2DM). The comparative analysis of monotherapy versus combination therapy reveals that while monotherapy remains effective in the early stages of T2DM, its efficacy diminishes as the disease progresses due to the multifactorial nature of hyperglycemia, including insulin resistance, β-cell dysfunction, and increased renal glucose reabsorption. Metformin, as a first-line monotherapy, provides a strong foundation for glycemic control due to its ability to suppress hepatic gluconeogenesis and enhance peripheral insulin sensitivity, but patients with progressive disease often require additional pharmacological interventions to maintain target glycemic levels.

REFERENCES

1. Kahn SE, Ahmed R. Mechanism of action and clinical efficacy of SGLT2 inhibitors in Type 2 Diabetes. *Diabetes Care*. 2020;43(3):508–518.

2. Rosenstock J, et al. Efficacy and safety of DPP-4 inhibitors in Type 2 Diabetes Mellitus. *Diabetologia*. 2019; 62:1234–1245.

3. DeFronzo RA, et al. Metformin in the treatment of Type 2 Diabetes: Mechanism and clinical outcomes. *Lancet Diabetes Endocrinol*. 2017; 5:247–258.

4. Holman RR, et al. Long-term outcomes of monotherapy versus combination therapy in Type 2 Diabetes. *N Engl J Med*. 2018; 379:1322–1333.

5. Chatterjee S, et al. GLP-1 receptor agonists: Benefits in glycemic control and weight management. *J Clin Endocrinol Metab*. 2021; 106:1482–1494.

6. American Diabetes Association. Standards of Medical Care in Diabetes—2022. *Diabetes Care*. 2022;45(Suppl 1): S1–S2.

7. Nathan DM, et al. Safety profiles of commonly used antidiabetic agents. *Diabetes Care*. 2015; 38:1777–1785.

8. Zinman B, et al. Cardiovascular outcomes of SGLT2 inhibitors in T2DM. *N Engl J Med*. 2016;374:2197–2208.

9. Maruthur NM, et al. Meta-analysis comparing monotherapy and combination therapy in T2DM. *BMJ*. 2016;354: i4576.

10. Bailey CJ, et al. Patient adherence and lifestyle factors in diabetes management. *Diabetes ObesMetab*. 2018; 20:1557–1565.

11. Gæde P, et al. Intensive glycemic control using combination therapy in T2DM. *Lancet Diabetes Endocrinol*. 2018; 6:555–564.

12. Pratley RE, et al. SGLT2 inhibitors combined with metformin: Synergistic effects. *Diabetes ObesMetab*. 2019; 21:123–133.

13. Ferrannini E, et al. Mechanistic benefits of GLP-1 receptor agonists in combination therapy. *Diabetes Care*. 2020; 43:129–140.

14. Buse JB, et al. Efficacy of triple therapy in uncontrolled Type 2 Diabetes. *Diabetes Care*. 2021; 44:212–220.

15. Li X, et al. Patient adherence and real-world effectiveness of mono- vs. combination therapy. *Diabetes Ther*. 2021; 12:789–802.

16. Zhang Y, et al. Cardiovascular and renal outcomes with SGLT2 inhibitors. *Cardiovasc Diabetol*. 2022;

21:108.

17. Kirkman MS, et al. Long-term safety of combination therapy in elderly T2DM patients. *J Diabetes Complications*. 2022; 36:107893.

18. Davies MJ, et al. Early combination therapy in T2DM with high HbA1c. *Lancet Diabetes Endocrinol*. 2023; 11:101–114.

19. Singh A, et al. Patient-centered approaches in mono- and multi-drug therapy selection. *J Clin Med*. 2023; 12:2104.

20. Mohan V, et al. Cost-effectiveness of combination therapy vs monotherapy in T2DM. *Diabetes Res Clin Pract*. 2024; 187:109910.